Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

5.515 -0.015 (-0.27%)
Streaming Delayed Price Updated: 12:41 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers SCYNEXIS (NASDAQ:SCYX) shares inc... 
Via Benzinga
Executives Buy Over $2.7M Of 4 Penny Stocks
Although producer prices in the Eurozone surged 26.2% year-over-year in December, hitting the highest level on record, there were a few notable insider trades. 
Via Benzinga
Recap: MannKind Q3 Earnings
MannKind (NASDAQ:MNKD) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings MannKind... 
Via Benzinga
Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro
Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ: 
Via Benzinga
MannKind's Debt Overview
Shares of MannKind (NASDAQ:MNKD) moved higher by 1.74% in the past three months. Before having a look at the importance of debt, let us look at how much debt MannKind has.... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of... 
Via Benzinga
Why Shares of MannKind Corporation Are Falling This Morning
Investors are hyperventilating after a delay for its inhaled medicine. 
Via The Motley Fool
Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet
Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the... 
Via Benzinga
Topics Stocks
34 Stocks Moving In Monday's Mid-Day Session
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
MNKD Stock: The Disappointing FDA News That Has MannKind Shares Diving Today
MannKind (MNKD) stock is taking a beating on Monday after releasing an update to investors concerning news from the FDA for Tyvaso DPI. 
Via InvestorPlace
Why MannKind Shares Are Falling Today
MannKind Corp (NASDAQ: MNKD) is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the... 
Via Benzinga
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease
The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion.... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Regencell Bioscience (NASDAQ:RGC)... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
MannKind's Return On Capital Employed Overview
According to Benzinga Pro data, during Q2, MannKind (NASDAQ:MNKD) posted sales of $23.28 million. Earnings were up 9.95%, but MannKind still reported an overall loss of $9.03... 
Via Benzinga
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary... 
Via Benzinga
MannKind Corporation (MNKD) Q2 2021 Earnings Call Transcript
MNKD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
MannKind: Q2 Earnings Insights
Shares of MannKind (NASDAQ:MNKD) moved higher by 3.1% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% year... 
Via Benzinga
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027
Via FinancialNewsMedia
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.